SCHEDULE 13G/A: RTW Investments and Dr. Roderick Wong Disclose 8.4% Passive Stake in Axsome Therapeutics

RTW Investments, LP and its Managing Partner, Dr. Roderick Wong, have disclosed a passive 8.4% beneficial ownership stake in Axsome Therapeutics, Inc. as of December 31, 2024.

Summary

• RTW Investments, LP and Roderick Wong, M.D. (collectively, the "Reporting Persons") have filed an Amendment No. 2 to Schedule 13G regarding their beneficial ownership in Axsome Therapeutics, Inc.
• As of December 31, 2024, the Reporting Persons collectively beneficially own 4,051,365 shares of Axsome Therapeutics, Inc. Common Stock.
• This ownership represents 8.4% of the company's outstanding Common Stock.
• The percentage is calculated based on 48,462,376 shares outstanding as of November 5, 2024, as reported in Axsome Therapeutics' Form 10-Q filed on November 12, 2024.
• RTW Investments, LP is a Delaware limited partnership and an investment adviser to certain funds (the "RTW Funds").
• Dr. Roderick Wong is the Managing Partner and Chief Investment Officer of RTW Investments.
• The shares are held by the RTW Funds, with RTW Investments and Dr. Wong having shared voting and dispositive power over these shares.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Axsome Therapeutics, Inc.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While a 13G is a factual disclosure, the presence of a significant, passive institutional investor like RTW Investments can be interpreted as a positive signal of confidence in the company's long-term value, without implying any immediate operational or financial changes.

Positives

• The disclosure of a significant 8.4% stake by an institutional investor like RTW Investments, LP, and its Chief Investment Officer, Dr. Roderick Wong, can be viewed as a vote of confidence in Axsome Therapeutics' long-term prospects.
• The passive nature of the investment, as indicated by the Schedule 13G filing, suggests a belief in the company's current management and strategic direction without intent to influence control.

Risks

• The document itself does not detail specific risks related to Axsome Therapeutics, Inc. beyond the inherent market risks associated with holding common stock.

Future Outlook

This Schedule 13G filing is a disclosure of current ownership and does not contain forward-looking statements or guidance regarding Axsome Therapeutics, Inc.'s future performance or strategic outlook.

Industry Context

This filing indicates continued significant institutional investment in Axsome Therapeutics, a company operating in the biotechnology and pharmaceutical sector. Such substantial passive stakes by specialized healthcare investors like RTW Investments are common and often reflect a long-term view on the potential of a company's drug pipeline or market position within the competitive biopharmaceutical landscape.

Stakeholder Impact

• Shareholders: The disclosure provides transparency regarding a significant institutional holder, which can influence investor sentiment and potentially provide a sense of stability or validation for the company's stock.
• Company Management: Awareness of a large passive investor may influence strategic decisions, though the 13G explicitly states no intent to influence control.

Key Dates

Keywords

Axsome Therapeutics, RTW Investments, Roderick Wong, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, SEC Filing, Biotechnology, Pharmaceuticals